Form 4: Silence Therapeutics CFO Acquires 375,000 Employee Share Options
SEC Form 4 Filing
Rhonda Lynette Hellums, CFO of Silence Therapeutics plc, was granted 375,000 employee share options on January 2, 2025.
Summary
- Rhonda Lynette Hellums, the Chief Financial Officer of Silence Therapeutics plc, filed a Form 4 with the SEC.
- The filing reports the grant of 375,000 employee share options on January 2, 2025.
- The exercise price of the options is $2.4.
- One-fourth of the shares will vest on January 2, 2026, and the remaining shares will vest in 36 equal monthly installments thereafter, contingent upon continuous service with the Issuer.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.
Industry Context
The granting of employee share options is a common practice in the biotechnology industry to incentivize and retain key personnel.
Stakeholder Impact
- The granting of share options aligns the CFO's interests with those of the shareholders, incentivizing her to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of earliest transaction (grant of employee share options) |
| 01/02/2025 | Grant date of 375,000 employee share options |
| 01/02/2035 | Expiration date of the employee share options |
| 01/06/2025 | Date of signature on the Form 4 filing |
| 01/02/2026 | Date when one-fourth of the shares subject to the option shall vest |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.